HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 — Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is delighted to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year.
The FDA’s Center for Veterinary Medicine (CVM) evaluates annual fees for animal drug applications. Sponsors developing innovative products can request a fee waiver each year under the “significant barrier to innovation” provision. Accordingly, Innocan submits an annual renewal request each year that includes a brief update on development progress and future plans. After reviewing the company’s latest submission, CVM has again granted Innocan a fee waiver for 2026. This marks the company’s third consecutive annual waiver, highlighting CVM’s ongoing recognition of Innocan’s innovation-driven animal health program.
The waiver pertains to the company’s Liposomal Technology–CBD (LPT-CBD) drug product candidate, which is being developed as a subcutaneous injection for managing chronic pain in dogs. In a blinded, crossover study conducted on osteoarthritic dogs, LPT-CBD showed a statistically significant reduction in pain and meaningful improvements in overall well-being compared to placebo (empty liposomes) (1). Combined with additional studies previously conducted on osteoarthritic dogs, these results provide robust evidence supporting LPT-CBD’s analgesic potential and its suitability as a treatment option for chronic pain in dogs.
“The veterinary market is open to new drug technologies that can address the limitations of current pain medications and offer a new alternative therapy,” said Dr’ Antonio Benitz, Innocan’s animal health advisor. The fee waiver granted by CVM for the third time, recognizing LPT-CBD’s innovation, strengthens Innocan’s progress toward delivering a new solution for chronic pain in dogs.
Dr. Eyal Kalo, Vice President of Research and Development at Innocan added, “U.S. pet ownership continues to grow, with an estimated 94 million households owning at least one pet.” (2) “Our technology is designed to meet the rising demand for safe, effective chronic pain solutions, combining demonstrated therapeutic potential with the convenience of a single, once-monthly administration”.
Reference:
(1) Yael Shilo-Benjamini et al, Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial, Front. Vet. Sci., 19 January 2026
(2) .
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with precise dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan operates through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information in this news release, including, without limitation, the company’s plans for human trials of its LPT-CBD platform, constitutes forward-looking information under applicable securities laws. By nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions regarding the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions, and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations in this news release. Key risks and uncertainties include, but are not limited to: global and local (national) economic, political, market, and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners, and competitors. There are also risks inherent in product distribution, including import/export matters and failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for market entry may change for various reasons, including inability to secure necessary regulatory requirements or the need for additional time to finalize and/or satisfy manufacturing and distribution arrangements. As a result, readers should not place undue reliance on the forward-looking information in this news release. A comprehensive discussion of other risks impacting Innocan can be found in Innocan’s public reports and filings available under Innocan’s profile at .
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may differ materially from forward-looking information. Innocan does not undertake to update, correct, or revise any forward-looking information as a result of new information, future events, or otherwise, except as required by applicable law.
Logo –
SOURCE Innocan Pharma Corporation